Lipid a-Induced responses in vivo

Advances in Experimental Medicine and Biology

Volumn 667, Issue , 2009, Pages 69-80

  Jeannin, Jean François ^a   Sassi, Nejia ^b   Paul, Catherine ^b   Martin, Amandine ^b   Bettaieb, Ali ^b  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; DT 5461; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIPID A; LIPID A DERIVATIVE; LOW DENSITY LIPOPROTEIN; OM 174; SDZ MRL 953; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BLOOD FLOW; CANCER PATIENT; CELLULAR IMMUNITY; CYANOSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEACETYLATION; DENDRITIC CELL; DEPHOSPHORYLATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG TOLERABILITY; FLUSHING; GENETIC ENGINEERING; HUMAN; IN VIVO STUDY; INNATE IMMUNITY; KUPFFER CELL; LIPOGENESIS; LOW DRUG DOSE; MELANOMA CELL; MOLECULAR DYNAMICS; NAUSEA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CARBOHYDRATE INTERACTION; PURIFICATION; RIGOR; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; LIPID A; NEOPLASMS;

ANIMALIA; MAMMALIA;

EID: 77952529781     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1603-7_7     Document Type: Article

References (108)

1. Rossignol DP, Wasan KM, Choo E et al. Safety, pharmacokinetics, pharmacodynamics and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healrhy volunteers. Antimicrob Agents Chemother 2004, 48(9) :3233-3240. (Pubitemid 39129312)
2. Hampton RY, Golenbock DT. Penman M et al. Recognition and plasma clearance of endotoxin by scavenger receptors. Nature 1991,352(6333):342-344. (Pubitemid 21912355)
3. Hopf U. Ramadori G. Moller B et al. Hepatocellular clearance function of bacterial Iipopolysaccharides and free lipid A in mice with endoroxic shock. AmJ Emerg Med 1984,2(1):13-19. (Pubitemid 14034386)
4. Munford RS, Andersen JM. Dietschy JM. Sites of tissue bind ing and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. J Clin Invest 1981; 68(6) :1503-1513. (Pubitemid 12194406)
5. Kleine B, Freudenberg MA, Galanos C. Excretion of radioactivity in faeces and urine of rats injected with 3H.14C-lipopolysaccharide. Br J Exp Pathol 1985; 66(3) :303-308. (Pubitemid 15032567)
6. Erwin AL. Munford RS. Deacylation of structurally diverse lipopolysaccharides by human acyloxyacyl hydrolase. J Biol Chern 1990,265(27):16444-16449.
7. Bentala H, VerweijWR. Huizinga-Van der Vlag A et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002, 18(6):561-566.
8. Reddy TS, Kishore V. Distribution and localization of monophosphoryl Iipid A in selected tissues of the rat. Immunopharmacol Immunoroxicol Ivve: 18(1):145-159.
9. Tobias PS. Soldau K. Ulevitch RJ. Isolation of a lipopolysaccharide- binding acute phase reactant from rabbit serum. J Exp Med 1986; 164(3) :777-793. (Pubitemid 16024834)
10. Jiang Z, Hong Z. Guo W et al. A synthetic peptide derived from bactericidal!permeabilit y-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 2004, 4(4) :527-537. (Pubitemid 38501660)
11. Appelmelk BJ. An YQ, Geerts M et al. Lactoferrin is a lipid A-binding protein. Infect Immun 1994, 62(6) :2628-2632. (Pubitemid 24157102)
12. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007, 19(1):3-10. (Pubitemid 46498750)
13. Azuma M, Matsuo A, Fujimoto Y et al. Inhibition of lipid A-mediated type I interferon induction by bacter icidallpermeability-increasing protein (BPI). Biochern Biophys Res Commun 2007, 354(2) :574-578. (Pubitemid 46161362)
14. Gazzano-Sanroro H. Meszaros K. Birr C et al. Competition between rBPI23, a recombinant fragment ofbactericidal!permeability-increasing protein and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994,62(4):1185-1191.
15. Chodaczek G. Zimecki M. LukasiewiczJ et al. A complex of lacroferrin with monophosphoryl lipid A is an efficient adjuvant of the humoral and cellular immune response in mice. Med Microbiol Immunol 2006, 195(4):207-216. (Pubitemid 44600381)
16. Lien E. ChowJC. Hawkins LD et al. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway,J Biol Chern 2001, 276(3):1873-1880. (Pubitemid 32111740)
17. Rasool O. Freer E. Moreno E ct aI. Effect of Brucella abortus lipopolysaccharide on oxidative metabolism and lysozyme release by human neutrophils. Infect Immun 1992; 60(4) :1699-1702.
18. Dunzendorfer S. Lee HK, Soldau K et al. Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS responses. FASEB J 2004; 18(10) :1117-1119. (Pubitemid 39561542)
19. Feist W; Ulmer AJ. Musehold J et al. Induction of tumor necrosis factor-alpha release by lipopolysaccharide and defined lipopolysaccharide partial structures. Immunobiology 1989; 179(4-5):293-307. (Pubitemid 19268306)
20. Ogawa T. Suda Y, Kashihara W et al. Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine 1997; 15(15) :1598-1605. (Pubitemid 27445740)
21. Jeannin JF, Onier N. Lagadec P et al. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology 1991; 101(3):726-733.
22. Korani S. Takada H. Tsujimoto M et al. Synthetic lipid A with endoroxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli rernutant. Infect Immun 1985; 49(1) :225-237. (Pubitemid 15062893)
23. Takahashi I. Kotani S. Takada H et al. Requirement of a properly acylated beta(I-6)-D-glucosamine disaccharide bisphosphate structure for efficient manifestation of full endotoxic and associated bioactivities of lipid A. Infect Immun 1987; 55(1) :57-68. (Pubitemid 17220366)
24. Caroff M. Cavaillon JM. Fitting C et al. Inability of pyrogenic. purified Borderella pertussis lipid A to induce interleukin-1 release by human monocytes. Infect Immun 1986; 54(2) :465-471. (Pubitemid 17171460)
25. Hurme M. Serkkola E. Comparison of interleukin 1 release and interleukin 1 mRNA expression of human monocytes activated by bacteriaIlipopolysaccharide or synthetic lipid A. Scand J Immunol 1989; 30(2) :259-263. (Pubitemid 19207570)
26. Kotani S. Takada H. Takahashi I et al. Low endotoxic activities of synthetic Salmonella-type lipid A with an additional acyloxyacyl group on the 2-amino group of beta (1-6) glucosamine disaccharide 1,4'-bisphosphate. Infect Immun 1986; 52(3) :872-884. (Pubitemid 16119858)
27. Arata S. Kasai N. Klein TW et al. Legionella pneumophila growth restriction and cytokine production by murine macrophages activated by a novel Pseudomonas lipid A. Infect Immun 1994; 62(2) :729-732. (Pubitemid 24033802)
28. Cavaillon JM. Fitting C. Caroff M et al. Dissociation of cell-associated interleukin -1 (IL-1) and IL-1 release induced by lipopolysaccharide and lipid A. Infect Immun 1989; 57(3):791-797. (Pubitemid 19064540)
29. Okernoro K. Kawasaki K. H anada K et al. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1 beta or activation of caspase-1. J Immunol 2006; 176(2) :1203-1208. (Pubitemid 43099724)
30. Martin M. Michalek SM. Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003; 71(5) :2498-2507. (Pubitemid 36519862)
31. Salkowski CA. Detore GR. Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon and interleukin-10 mRNA production in murine macrophages. Infect Immun 1997; 65(8) :3239-3247. (Pubitemid 27342405)
32. Galanos C. Lehmann V, Luderitz O. et al. Endoroxic properties of chemically synthesized lipid A part structures. Comparison of synrhetic lipid A precursor and synthetic analogues with biosynrhetic lipid A precursor and free lipid A. Eur J Biochem 1984; 140(2):221-227. (Pubitemid 14139826)
33. Saha DC. Barua RS. Astiz ME et al. Monophosphoryl lipid A stimulated up-regulation of reactive oxygen intermediates in human monocytes in vitro. J Leukoc Biol 2001; 70(3):381-385. (Pubitemid 32826125)
34. Dahinden CA. Fehr J. Hugli TE. Role of cell surface contact in the kinetics of superoxide production by granulocytes. J Clin Invest 1983; 72(1) :113-121. (Pubitemid 13026634)
35. Chen YF. Solem L. Johnson AG. Activation of macrophages from aging mice by detoxified lipid A. J Leukoc Biol 1991; 49(4) :416-422.
36. Dijksrra J. Mellors JW; Ryan JL. Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A. Infect Immun 1989; 57(11) :3357-3363. (Pubitemid 19259862)
37. Saha DC. Astiz ME. Lin RY et al. Monophosphoryl lipid A stimulated up-regulation of nitric oxide synthase and nitric oxide release by human monocytes in vitro. Immunopharmacology 1997; 37(2-3):175-184. (Pubitemid 27471034)
38. Tanarnoto K. Azumi S. Haishima Y et al. Endotoxic properties of free lipid A from Porphyromonas gingivalis. Microbiology 1997; 143(Pt1):63-71. (Pubitemid 27072960)
39. Lopez-Urrutia L. Alonso A. Nieto ML et al. Lipopolysaccharides of Brucella abortus and Brucella melitensis induce nitric oxide synthesis in rat peritoneal macrophage s. Infect Immun 2000; 68(3) :1740-1745. (Pubitemid 30108585)
40. Renzi PM. Lee CH. Anti-lipid A monoclonal antibodies alter human endothelial cell ICAM-1 expression in vitro. Shock 1995; 3(5) :329-336.
41. Dahinden C. Galanos C. Fehr J. Granulocyte activation by endotoxin. 1.Correlation between adherence and other granulocyte functions and role of endotoxin structure on biologic activity. J Immunol 1983; 130(2):857-862. (Pubitemid 13186318)
42. Kang BH. Manderschied BD. Huang YC et al. Contrasting response oflung parenchymal cellsto instilled TNF alpha and IFN gamma: the inducibility of specific cell ICAM-1 in vivo. Am J Respir Cell Mol Biol 1996; 15(4):540-550. (Pubitemid 126440581)
43. Kotani S. Takada H. Tsujimoto M et al. Immunobiological activities of synthetic lipid A analogs and related compounds as compared with those of bacterial lipopolysaccharide. reglycollpld, lipid A and muramyl dipeptide. Infect Immun 1983; 41(2):758-773. (Pubitemid 13074635)
44. Tanamoto K. Zahringer U. McKenzie GR et al. Biological activities of synthetic lipid A analogs: pyrogenicicy,lethal toxicity. anticomplement activity and induction of gelation of Limulus amoebocyte lysate. Infect Immun 1984; 44(2):421-426. (Pubitemid 14139008)
45. Ramsey RB. Hamner MB. Alving BM et al. Effects of lipid A and liposomes containing lipid A on platelet and fibrinogen production in rabbits. Blood 1980; 56(2):307-310. (Pubitemid 10043433)
46. GrabarekJ, Timmons S. Hawiger J. Modulation of human platelet protein kinase C by endotoxic lipid A. J Clin Invest 1988; 82(3) :964-971.
47. Takada H. Korani S, Tsujimoto M et al. Immunopharmacological activities of a synthetic counterpart of a biosynrheric lipid A precursor molecule and of its analogs. Infect Immun 1985; 48(1) :219-227. (Pubitemid 15076456)
48. Verghese MW; Snyderman R. Endotoxin (LPS) stimulates in vitro migration of macrophages from LPS-resistant mice but not from LPS-sensitive mice. J Immunol1982; 128(2) :608-613. (Pubitemid 12168409)
49. Sagara-Ishijima N, Furuhama K. Toxic characteristics of the synthetic lipid A derivative DT-5461 in tats and monkeys. Toxicol Sci 1999; 49(2) :324-331. (Pubitemid 29300420)
50. Ismaili J, Rennesson J. Aksoy E et al. Monophosphoryllipid A activates both human dendritic cells and T-cells. J Immunol 2002; 168(2):926-932. (Pubitemid 34049597)
51. Lapteva N, Seeehammagari MR, Hanks BA et al. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4ligation. Cancer Res 2007; 67(21) :10528-10537. (Pubitemid 350070829)
52. De Becker G. Moulin V. Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Inr Immunol 2000; 12(6):807-815. (Pubitemid 30410453)
53. Pajak B, Garze V. Davies G et al. The adjuvant OM -174 induces both the migration and maturat ion of murine dendritic cells in vivo. Vaccine 2003; 21(9-10):836-842. (Pubitemid 36126416)
54. Ten Brinke A, Karsten ML, Dicker MC et al. The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte -derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine 2007; 25(41) :7145-7152. (Pubitemid 47464674)
55. Thompson BS. Chilton PM, Ward JR et al. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T-cells. J Leukoc Biol 2005; 78(6) :1273-1280. (Pubitemid 41779233)
56. Evans JT, Cluff CW, Johnson DA et al. Enhancement of antigen- specificimmunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003; 2(2) :219-229. (Pubitemid 36559927)
57. Baldridge JR. McGowan P, EvansJT et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monorhcrapcutic agents. Expert Opin BiolTher 2004; 4(7):1129-1138. (Pubitemid 38937554)
58. Kumazawa E, Tohgo A. Soga T et al. Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models. Cancer Immunol Immunother 1992; 35(5) :307-314.
59. Yang D. Satoh M, Ueda H et al. Activation of rumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 1994; 38(5) :287-293. (Pubitemid 24128005)
60. On ier N, Hilpert S, Reveneau S et al. Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Inr J Cancer 1999; 81(5):755-760. (Pubitemid 29214386)
61. Vosika GJ, Barr C, Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Irnmunorher 1984; 18(2):107-112. (Pubitemid 15213363)
62. de Bono JS, Dalgleish AG, Carmichael J et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000; 6(2) :397-405. (Pubitemid 30111456)
63. Ishida H, Fujii E, Irie K et al. Role of inflammatory mediators in lipid A analogue (ONO-4007)-induced vascular permeability change in mouse skin. Br J Pharmacol2000; 130(6):1235-1240.
64. Lam C. Schutze E, Hildebrandt J et al. SDZ MRL 953. a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemorher 1991; 35(3) :500-505.
65. Ali KH, Feeley TW, Bieber M et al. Cardiovascular effect of intravenous lipid A in rabbits. Circ Shock 1987; 23(4) :285-293. (Pubitemid 17168036)
66. Kiani A, Tschiersch A. Gaboriau E et al. Downregulation of the proinflammatory cyrokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997; 90(4) :1673-1683. (Pubitemid 27355442)
67. Madonna GS. Peterson JE. Ribi EE et al. Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative. monophosphoryl lipid A. Infect Immun 1986; 52(1):6-11. (Pubitemid 16137671)
68. Astiz ME, Rackow EC, Kim YB et al. Monophosphoryllipid A induces tolerance to the lethal hemodynamic effects of endotoxernia. Circ Shock 1991; 33(2):92-97.
69. Zuckerman SH. Qureshi N. In vivo inhibition of lipopolysaccharide-induced lethality and tumor necrosis factor synthesis by Rhodobacter sphaeroides diphosphoryllipid A is dependent on corticosterone induction. Infect Immun 1992; 60(7):2581-2587.
70. Matsuura M. Kiso M. Hasegawa A et al. Multistep regulation mechanisms for tolerance induction to lipopolysaccharide lethality in the tumor-necrosis- factor-alpha-mediated parhway. Application of nontoxic monosaccharide lipid A analogues for elucidat ion of mechanisms. Eur J Biochem 1994; 221(1) :335-341. (Pubitemid 24120578)
71. Henricson BE. Benjamin WR. VogelSN. Differential cytokine induction by doses oflipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun 1990; 58(8) :2429-2437. (Pubitemid 20228221)
72. Beutler B, Krochin N. Milsark IW et al, Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232(4753):977-980. (Pubitemid 16085400)
73. Amano Y. Lee SW; Allison AC. Inhibition by glucocorticoids of the formation of interleukin-1 alpha, inrerleukin-1 beta and interleukin-6: mediation by decreased mRNA stability. Mol Pharmacol 1993; 43(2):176-182. (Pubitemid 23055060)
74. Henricson BE, Perera PY. Qureshi N et al. Rhodopseudomonas sphaeroides lipid A derivatives block in vitro induction of tumor necrosis factor and endotoxin tolerance by smooth lipopolysaccharide and monophosphoryl lipid A. Infect Immun 1992; 60(10):4285-4290.
75. Galanos C, Luderitz 0, Rietschel ET et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985; 148(1) :1-5. (Pubitemid 15080991)
76. Knopf HP, Otto F, Engelhardt R et al. Discordant adaptation of human peritoneal macrophages to stimulation by lipopolysaccharide and the synthetic lipid A analogue SDZ MRL 953. Down-regulation of TNF-alpha and IL-6 is paralleled by an up-regulation of IL-1 beta and granulocyte colony-stimulating factor expression. J Immunol1994; 153(1):287-299.
77. Kitchens RL, Ulevirch RJ, Munford RS. Lipopol ysaccharide (LPS) partial structures inhib it responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD 14-mediated pathway. J Exp Med 1992; 176(2):485-494.
78. Carswell EA. Old LJ, Kassel RL et al. An endotoxin-induced serum facror that causes necrosis of rumors. Proc Natl Acad Sci USA 1975; 72(9) :3666-3670.
79. van de W iel PA, van der Pijl A, Bloksma N. Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity. Cancer ImmunolImmunother 1991; 33(2) :115-120.
80. Kuramitsu Y, Nishibe M. Ohiro Y et al. A new synthetic lipid A analog, ONO-4007. stimulates the production of tumor necrosis factor-alpha in tumor tissues. resulting in the rejection of transplanted rat hepatoma cells. Anticancer Drugs 1997; 8(5) :500-508. (Pubitemid 27310920)
81. Akimoto T, Kumazawa E. Jimbo T et al. Antitumor effect ofDT-546Ia, a synthetic low-toxicity lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation. Int J Immunopharmacol 1994; 16(11):887-893.
82. Sato K, Yoo YC. Mochizuki M et al. Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461. Jpn J Cancer Res 1995; 86(4):374-382.
83. Matsumoto N. Oida H, Aze Y et al. Intrarumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog. Anticancer Res 1998; 18(6A):4283-4289. (Pubitemid 29043646)
84. Kumazawa E. Akimoto T. Kira Y et al. Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent antitumor effects of DT-5461, a synthetic lipid A analog. J Irnmunother Emphasis Tumor Immunol1995 ; 17(3):141-150.
85. Onier N. Hilpert S. Arnould L et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis 1999; 17(4):299-306. (Pubitemid 29477575)
86. Onier N, Lejeune P, Martin M et al. Involvement of T-lymphocytes in curative effect of a new immunomodulator OM 163 on rat colon cancer metastases. Eur J Cancer 1993; 29A(14) :2003-2009. (Pubitemid 23324362)
87. Dighe AS. Richards E. Old LJ et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1(6):447-456.
88. Matsushita K. Kuramitsu Y, Ohiro Y et al. ONO-4007, a synthetic lipid A analog, induces Th 1-type immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages. Int J Oncol 2003; 23(2):489-493.
89. Hibbs JB Jr. Taintor RR, VavrinZ et al. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157(1):87-94. (Pubitemid 19004828)
90. Jeannin JF, Leon L. Cortier M et al. Nitric oxide-induced resistance or sensitization to death in tumor cells. Nitric Oxide 2008; 19(2):158-163.
91. Lejeune P, Lagadec P, Onier N et al. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol1994; 152(10):5077-5083. (Pubitemid 24139103)
92. Larmonier CB. Arnould L. Larmonier N et al. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Inr J Mol Med 2004; 13(3):355-361.
93. Lagadec P. Raynal S. Lieubeau B et al. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development. Am J Parhol 1999; 154(6):1867-1876. (Pubitemid 29262870)
94. Gauthier N. Lohm S. Touzery C et al. Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis 2004; 25(9):1559-1565. (Pubitemid 39214297)
95. Alexander P. Evans R. Endotoxin and double stranded RNA render macrophages cytotoxic. Nat New Biol 1971; 232(29) :76-78.
96. Satoh M. Ando S. Shinoda T et al. Clearance of bacteriallipopolysaccharides and lipid A by the liver and the role of argininosuccinate synthase. Innate Immun 2008; 14(1):51-60.
97. Verreck FA, de Boer T. Langenberg DM et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 2004; 101(13):4560-4565. (Pubitemid 38437450)
98. Nakatsuka M. Kumazawa Y, Homma JY et al. Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GLA-60. Int J Immunopharmacol 1991; 13(1):11-19.
99. Takahashi M. Ogasawara K. Takeda K et al. LPS induces NK1.1+ alpha beta T-cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 1996; 156(7):2436-2442. (Pubitemid 26091568)
100. D'Agostini C. Pica F. Febbraro G et al. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Inr Immunopharmacol 2005; 5(7-8):1205-1212. (Pubitemid 40725714)
101. Bhardwaj N. Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol Med 2001; 7(9) :388-394. (Pubitemid 32823987)
102. Parr I, Wheeler E. Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. BrJ Cancer 1973; 27(5):370-389.
103. Andreani V. Gatti G. Simonella L et al. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007; 67(21):10519-10527. (Pubitemid 350070828)
104. Matsushita K. Kobayashi M. Totsuka Y et al. ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-alpha. Anticancer Drugs 1998; 9(3) :273-282. (Pubitemid 28186525)
105. Matsumoto N. Aze Y, Akimoto A et al. Restoration of immune responses in tumor-bearing mice by ONO-4007. an antitumor lipid A derivative. Immunopharmacology 1997; 36(1):69-78. (Pubitemid 27153479)
106. Akimoro T. Kumazawa E. Jimbo T et al. DT-5461a, an antitumor synthetic lipid a analog, causesselective blood flow reduction in tumor tissue. Anticancer Res 1995; 15(1):105-107.
107. Jimbo T. Akirnoto T. Tohgo A. Systemic administrat ion of a synthetic lipid A derivative. DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits. Anticancer Res 1996; 16(1):359-364. (Pubitemid 26129064)
108. Saiki I. Saro K. Yoo YC et al. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60).Int J Cancer 1992; 51(4):641-645.